Table 1.
Characteristics of prostate cancer cohort by treatment group.
| Untreated | Radiotherapya | Radical prostatectomya | ADTa | ADT type | |||||
|---|---|---|---|---|---|---|---|---|---|
| GnRHa | Degarelixa | Bicalutamide 150 mga | Other antiandrogena | ||||||
| Year of diagnosis: | 2009 | 686 (14%) | 134 (13%) | 285 (12%) | 1728 (14%) | 1550 (15%) | 5 (1%) | 88 (20%) | 81 (13%) |
| 2010–11 | 1297 (26%) | 293 (28%) | 657 (28%) | 3371 (28%) | 3015 (29%) | 22 (6%) | 123 (27%) | 206 (34%) | |
| 2012–13 | 1436 (29%) | 381 (36%) | 657 (28%) | 3397 (28%) | 2989 (29%) | 114 (29%) | 116 (26%) | 177 (29%) | |
| 2014–15 | 1484 (30%) | 243 (23%) | 723 (31%) | 3444 (29%) | 2926 (28%) | 246 (64%) | 124 (27%) | 145 (24%) | |
| Age at diagnosis: | <60 | 593 (12%) | 233 (22%) | 696 (30%) | 886 (7%) | 776 (7%) | 23 (6%) | 46 (10%) | 39 (6%) |
| 60–69 | 1789 (36%) | 496 (47%) | 1371 (59%) | 3848 (32%) | 3379 (32%) | 112 (29%) | 168 (37%) | 187 (31%) | |
| 70–79 | 1543 (31%) | 309 (29%) | 251–255c | 5017 (42%) | 4459 (43%) | 156 (40%) | 167 (37%) | 232 (38%) | |
| ≥ 90 | 978 (20%) | 13 (1%) | 2189 (18%) | 1866 (18%) | 96 (25%) | 70 (16%) | 151 (25%) | ||
| Deprivation: | 5th fifth (most deprived) | 1211 (25%) | 273 (26%) | 696 (30%) | 2541 (21%) | 2255 (22%) | 61 (16%) | 109 (24%) | 113 (19%) |
| Gleason score: | ≤ 6 | 1808 (62%) | 231 (37%) | 441 (32%) | 658 (10%) | 596 (10%) | 19 (5%) | 35 (15%) | 8 (2%) |
| 7 | 505 (17%) | 311 (50%) | 840 (61%) | 2326 (34%) | 2084 (35%) | 45 (13%) | 124 (52%) | 72 (22%) | |
| 8 | 41 (1%) | 35 (6%) | 69 (5%) | 812 (12%) | 727 (12%) | 27 (8%) | 19 (8%) | 39 (12%) | |
| 9 | 51 (2%) | 27 (4%) | 30 (2%) | 1546 (23%) | 1361 (23%) | 71 (20%) | 31 (13%) | 81 (25%) | |
| 10 | 5 (0%) | 6 (1%) | < 5 | 151 (2%) | 110 (2%) | 17 (5%) | < 5 | 21 (7%) | |
| Missing | 510 (17%) | 14 (2%) | < 5 | 1348 (20%) | 1037 (18%) | 181 (50%) | 27–31c | 101 (31%) | |
| T stageb: | 1 | 870 (30%) | 92 (15%) | 54 (4%) | 461 (7%) | 376 (6%) | 36 (10%) | 36 (15%) | 13 (4%) |
| 2 | 1401 (48%) | 430 (69%) | 883 (64%) | 2020 (30%) | 1794 (30%) | 49 (14%) | 98 (41%) | 77 (24%) | |
| 3 | 219 (8%) | 82 (13%) | 432 (31%) | 2801 (41%) | 2482 (42%) | 103 (29%) | 80 (33%) | 135 (42%) | |
| 4 | 57 (2%) | 6 (1%) | 5 (0%) | 706 (10%) | 600 (10%) | 78 (22%) | < 5 | 24 (7%) | |
| X | 373 (13%) | 14 (2%) | 6 (0%) | 853 (12%) | 663 (11%) | 94 (26%) | 22–26c | 73 (23%) | |
| N stageb: | 0 | 1946 (67%) | 543 (87%) | 1233 (89%) | 3881 (57%) | 3497 (59%) | 72 (20%) | 180 (75%) | 131 (41%) |
| 1 | 64 (2%) | 18 (3%) | 23 (2%) | 1181 (17%) | 1004 (17%) | 99 (28%) | 13 (5%) | 63 (20%) | |
| X | 910 (31%) | 63 (10%) | 124 (9%) | 1779 (26%) | 1414 (24%) | 189 (53%) | 47 (20%) | 128 (40%) | |
| M stageb: | 0 | 1665 (57%) | 493 (79%) | 1002 (73%) | 3826 (56%) | 3459 (58%) | 58 (16%) | 161 (67%) | 147 (46%) |
| 1 | 217 (7%) | 8 (1%) | < 5 | 2022 (30%) | 1616 (27%) | 263 (73%) | 12 (5%) | 128 (40%) | |
| X | 1038 (36%) | 123 (20%) | 372–378c | 993 (15%) | 840 (14%) | 39 (11%) | 67 (28%) | 47 (15%) | |
| Medications in year priord: | Aspirin | 1471 (30%) | 230 (22%) | 293 (13%) | 3696 (31%) | 3209 (31%) | 146 (38%) | 148 (33%) | 188 (31%) |
| Statin | 2078 (42%) | 408 (39%) | 637 (27%) | 5414 (45%) | 4722 (45%) | 206 (53%) | 214 (47%) | 266 (44%) | |
| Nitrate | 493 (10%) | 73 (7%) | 72 (3%) | 1213 (10%) | 1035 (10%) | 64 (17%) | 64 (14%) | 49 (8%) | |
| Metformin | 321 (7%) | 64 (6%) | 86 (4%) | 951 (8%) | 818 (8%) | 50 (13%) | 40 (9%) | 43 (7%) | |
| Comorbidities priore: | Angina | 793 (16%) | 111 (11%) | 110 (5%) | 1880 (16%) | 1593 (15%) | 94 (24%) | 98 (22%) | 90 (15%) |
| MI | 234 (5%) | 38 (4%) | 37 (2%) | 607 (5%) | 508 (5%) | 37 (10%) | 32 (7%) | 29 (5%) | |
| Heart failure | 208 (4%) | 21 (2%) | 13 (1%) | 468 (4%) | 376 (4%) | 31 (8%) | 30 (7%) | 31 (5%) | |
| Stroke | 235 (5%) | 25 (2%) | 23 (1%) | 519 (4%) | 443 (4%) | 29 (7%) | 20 (4%) | 27 (4%) | |
| VTE | 102 (2%) | 9 (1%) | 20 (1%) | 181 (2%) | 157 (1%) | 5 (1%) | 8 (2%) | 11 (2%) | |
| Arrhythmia | 542 (11%) | 50 (5%) | 70 (3%) | 1137 (10%) | 955 (9%) | 67 (17%) | 57 (13%) | 57 (9%) | |
| Any cardiovascular | 1661 (34%) | 233 (22%) | 367 (16%) | 3818 (32%) | 3267 (31%) | 173 (45%) | 179 (40%) | 194 (32%) | |
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone agonist; MI, myocardial infarction; VTE, venous thromboembolism.
Participants allocated to the following mutually exclusive treatment categories based upon any use after diagnosis: ADT (with or without RP or RT), RP (with or without RT but without ADT) and RT (without ADT or RP). ADT users allocated to the following categories based upon any use after prostate cancer diagnosis: GnRH (with or without any other ADT), degarelix (with or without an antiandrogen but without GnRH), bicalutamide 150 mg (with or without any other antiandrogen but without degarelix and GnRH) and other antiandrogen (without GnRH, deagaralex, bicalutamide 150 mg).
Stage unavailable for prostate cancer patients diagnosed 2009 to 2011.
Range given to avoid disclosure of small counts.
Medications at any time prior to prostate cancer diagnosis.
Comorbidities at any time prior to prostate cancer diagnosis.